Cargando…

Effect of Pemafibrate on Hemorheology in Patients with Hypertriglyceridemia and Aggravated Blood Fluidity Associated with Type 2 Diabetes or Metabolic Syndrome

Persistent high serum triglyceride (TG) and free fatty acid (FFA) levels, which are common in metabolic syndrome and type 2 diabetes, are risk factors for cardiovascular events because of exacerbated hemorheology. To explore the effects of pemafibrate, a selective peroxisome proliferator-activated r...

Descripción completa

Detalles Bibliográficos
Autores principales:	Iwakura, Tomohiro, Yasu, Takanori, Tomoe, Takashi, Ueno, Asuka, Sugiyama, Takushi, Otani, Naoyuki, Kawamoto, Shinya, Nakajima, Hiroyuki
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Brief Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9962113/ https://www.ncbi.nlm.nih.gov/pubmed/36836015 http://dx.doi.org/10.3390/jcm12041481

Ejemplares similares

Recent Advances in the Treatment of Pulmonary Arterial Hypertension
por: Otani, Naoyuki, et al.
Publicado: (2022)

Half Dose Once-Daily Pemafibrate Effectively Improved Hypertriglyceridemia in Real Practice
por: Iitake, Chie, et al.
Publicado: (2019)

A Significant Effect of Pemafibrate on Hepatic Steatosis and Fibrosis Indexes in Patients With Hypertriglyceridemia
por: Katsuyama, Hisayuki, et al.
Publicado: (2023)

Circulating cell clusters aggravate the hemorheological abnormalities in COVID-19
por: Javadi, Elahe, et al.
Publicado: (2022)

Efficacy and Safety of Low-Dose Pemafibrate Therapy for Hypertriglyceridemia in Patients with Type 2 Diabetes
por: Bando, Hidenori, et al.
Publicado: (2021)

Homozygous familial hypercholesterolemia with stenosis of the left anterior descending coronary artery successfully treated with weekly low‐density lipoprotein apheresis for 16 years without percutaneous coronary intervention
por: Yasu, Takanori, et al.
Publicado: (2019)

Efficacy and Safety of Pemafibrate Versus Bezafibrate to Treat Patients with Hypertriglyceridemia: A Randomized Crossover Study
por: Nakamura, Akihiro, et al.
Publicado: (2023)

Efficacy and Safety of Pemafibrate Versus Bezafibrate to Treat Patients with Hypertriglyceridemia: A Randomized Crossover Study
por: Nakamura, Akihiro, et al.
Publicado: (2023)

Effects of Pemafibrate in Patients with Stroke and Hypertriglyceridemia: Baseline Cerebral Artery Diseases and 3-Month Laboratory Outcomes
por: Hoshino, Takao, et al.
Publicado: (2022)

Impact of Pemafibrate Therapy on Reducing Small Dense Low-Density-Lipoprotein-Cholesterol Levels in Patients with Hypertriglyceridemia
por: Hida, Yuki, et al.
Publicado: (2023)

A Novel Selective PPARα Modulator (SPPARMα), K-877 (Pemafibrate), Attenuates Postprandial Hypertriglyceridemia in Mice
por: Sairyo, Masami, et al.
Publicado: (2018)

Marked effects of novel selective peroxisome proliferator-activated receptor α modulator, pemafibrate in severe hypertriglyceridemia: preliminary report
por: Iitake, Chie, et al.
Publicado: (2020)

Long-Term Tailor-Made Exercise Intervention Reduces the Risk of Developing Cardiovascular Diseases and All-Cause Mortality in Patients with Diabetic Kidney Disease
por: Tamiya, Hajime, et al.
Publicado: (2023)

Erratum:A Novel Selective PPARα Modulator (SPPARMα), K-877 (Pemafibrate), Attenuates Postprandial Hypertriglyceridemia in Mice
por: Sairyo, Masami, et al.
Publicado: (2018)

Effect of 48‐week pemafibrate on non‐alcoholic fatty liver disease with hypertriglyceridemia, as evaluated by the FibroScan‐aspartate aminotransferase score
por: Hatanaka, Takeshi, et al.
Publicado: (2021)

Hemorheology and Microvascular Disorders
por: Cho, Young-Il, et al.
Publicado: (2011)

Impaired Hemorheology in Exacerbations of COPD
por: Ugurlu, Erhan, et al.
Publicado: (2017)

Aggravation of Hypertriglyceridemia and Acute Pancreatitis in a Bipolar Patient Treated with Quetiapine
por: Liou, Li-Syue, et al.
Publicado: (2014)

Pathophysiology and Treatment of Chronic Thromboembolic Pulmonary Hypertension
por: Otani, Naoyuki, et al.
Publicado: (2023)

Effects of a novel selective peroxisome proliferator‐activated receptor‐α modulator, pemafibrate, on hepatic and peripheral glucose uptake in patients with hypertriglyceridemia and insulin resistance
por: Matsuba, Ikuro, et al.
Publicado: (2018)

Pemafibrate improves liver dysfunction and non-invasive surrogates for liver fibrosis in patients with non-alcoholic fatty liver disease with hypertriglyceridemia: a multicenter study
por: Morishita, Asahiro, et al.
Publicado: (2022)

Favorable Effect of Pemafibrate on Insulin Resistance and β-Cell Function in Subjects with Type 2 Diabetes and Hypertriglyceridemia: A Subanalysis of the PARM-T2D Study
por: Nomoto, Hiroshi, et al.
Publicado: (2023)

Effects of whole-body neuromuscular electrical stimulation device on hemodynamics, arrhythmia, and sublingual microcirculation
por: Hoshiai, Megumi, et al.
Publicado: (2021)

Hemorheological and Microcirculatory Relations of Acute Pancreatitis
por: Kotan, Robert, et al.
Publicado: (2022)

Impact of Pemafibrate in Patients with Hypertriglyceridemia and Metabolic Dysfunction-associated Fatty Liver Disease Pathologically Diagnosed with Non-alcoholic Steatohepatitis: A Retrospective, Single-arm Study
por: Hatanaka, Takeshi, et al.
Publicado: (2021)

Defining Lineage-Specific Membrane Fluidity Signatures that Regulate Adhesion Kinetics
por: Matsuzaki, Takahisa, et al.
Publicado: (2018)

Fluidity of the body
por: Kothari, Manu, et al.
Publicado: (2014)

Finding Fluidity
por: Kenchington-Evans, Lily
Publicado: (2022)

Pemafibrate decreases triglycerides and small, dense LDL, but increases LDL-C depending on baseline triglycerides and LDL-C in type 2 diabetes patients with hypertriglyceridemia: an observational study
por: Komiya, Ichiro, et al.
Publicado: (2021)

Decreased Physical and Daily Living Activities in Patients with Peripheral Arterial Disease on Hemodialysis
por: Tamura, Yuma, et al.
Publicado: (2022)

Immune and hemorheological changes in Chronic Fatigue Syndrome
por: Brenu, Ekua W, et al.
Publicado: (2010)

Hemorheological effects of amlodipine in spontaneously hypertensive rats
por: Shamanaev, Aleksandr Y., et al.
Publicado: (2017)

Erythrocytes morphology and hemorheology in severe bacterial infection
por: Silva, Ayrles FB, et al.
Publicado: (2019)

Changes of Hematological and Hemorheological Parameters in Rabbits with Hypercholesterolemia
por: Tanczos, Bence, et al.
Publicado: (2021)

Effects of body composition and liver function after long-term pemafibrate treatment on dyslipidemia-associated non-alcoholic fatty liver disease
por: Ishikawa, Toru, et al.
Publicado: (2023)

Fluidity onset in graphene
por: Bandurin, Denis A., et al.
Publicado: (2018)

Systemic Transitional Fluidity
por: Ali, S. Mahmud
Publicado: (2015)

Disrupting enzyme fluidity
por: Anand, Ganesh Srinivasan
Publicado: (2021)

Pemafibrate Ameliorates Liver Dysfunction and Fatty Liver in Patients with Non-Alcoholic Fatty Liver Disease with Hypertriglyceridemia: A Retrospective Study with the Outcome after a Mid-Term Follow-Up
por: Ikeda, Suguru, et al.
Publicado: (2021)

Prospective randomized comparative study of the effect of pemafibrate add‐on or double statin dose on small dense low‐density lipoprotein‐cholesterol in patients with type 2 diabetes and hypertriglyceridemia on statin therapy
por: Hirano, Tsutomu, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_rdhlep3i7ai3n6o8qf8jdp162o